Personlized Products Erythromycin For Oral Suspension - Artesunate +sulformethoxine+ pyrimethamine tabs – KeMing Medicines Detail:
FOB Price | Inquiry |
Min.Order Quantity | 1,000,000 tablets |
Supply Ability | 120,000,000 tablets/Month |
Port | Shanghai |
Payment Terms | T/T in advance |
Product Detail | |
Product name | Artesunate +sulformethoxine+ pyrimethamine tabs |
Specification | 100mg+525mg |
Description | A white tablets |
Standard | USP |
Package | 6+3’s/blister |
Transportation | Ocean,Land,Air |
Certificate | GMP |
Price | Inquiry |
Quality guaranteeperiod | for 36 months |
Product Description | AMK-A tablets is recommended for use for malaria treatment,especially for preventing malaria
caused Plasmodium falciparum that are resistant to chloroquine,also used in the treatment of cerebral malaria and emergency treatment of critical cases. administered as a single dose on D1,with the first dose of artesunate. |
Product detail pictures:
Related Product Guide:
Cholesterol Drugs and Low Vitamin D Along With Other Hormone Levels
Prescription Drugs Can Lead to Vitamin and Mineral Deficiencies
Our company has been focusing on brand strategy. Customers' satisfaction is our best advertising. We also supply OEM service for Personlized Products Erythromycin For Oral Suspension - Artesunate +sulformethoxine+ pyrimethamine tabs – KeMing Medicines, The product will supply to all over the world, such as: Canberra, Angola, Ukraine, Our company absorbs new ideas, strict quality control, a full range of service tracking, and adhere to make high-quality products. Our business aims to "honest and trustworthy, favorable price, customer first", so we won the trust of the majority of customers! If you are interested in our products and services, please do not hesitate to contact us!
By Klemen Hrovat from New Zealand - 2017.03.08 14:45
We always believe that the details decides the company's product quality, in this respect, the company conform our requirements and the goods are meet our expectations.
By Rosemary from Sheffield - 2018.09.08 17:09